Clinical trials
Alzheimer Disease or Associated Disorder clinical trials
Below are recruiting alzheimer disease or associated disorder clinical trials, each written for real people, not researchers. We’re tracking 1,805 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06702124RecruitingPhase 3
Rotigotine patch with rivastigmine for mild to moderate Alzheimer's
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
Rome, ItalyAges 50–85 - NCT04312399Recruiting
Hormone treatment study for Alzheimer risk in postmenopausal women
This study looks at whether hormone treatment can help prevent or slow Alzheimer’s disease in women who have gone through menopause. It may help by testing a hormone-based approach in a carefully selected group.
GhentAges 40–65 - NCT07457125RecruitingPhase 1/Phase 2
Exosome therapy for mild to moderate Alzheimer's disease
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
BeijingAges 50 years+ - NCT07456332Enrolling by invitation
Digital lifestyle program for weight loss with HIV and fatty liver
This trial tests a digital lifestyle program (diet and activity coaching) to help people with HIV and fatty liver disease lose weight. It aims to see if the program can reduce body fat in the liver and improve overall health.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT07450391RecruitingPhase 1/Phase 2
EBV-targeted cell therapy for EBV-related lymph disorders
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
Beijing, Beijing MunicipalityAges 18–70 - NCT07409506Recruiting
How caregivers help people with Alzheimer's
This study looks at the support that caregivers provide to people with Alzheimer's disease at different stages. It helps researchers understand how caregiving changes over time, which can lead to better support for both patients and their families.
VilleurbanneAges 60 years+ - NCT07399171RecruitingPhase 2
Testing HT-4253 to prevent Alzheimer's in APOE4 carriers
This trial tests an experimental drug called HT-4253 to see if it can prevent Alzheimer's disease in people who are at higher genetic risk (carry the APOE4 gene) and have early signs of amyloid buildup in the brain. If you qualify, you would take the drug or a placebo and be monitored over time.
Abu Dhabi, Abu Dhabi EmirateAges 50–75 - NCT06833645Recruiting
PET scans to spot early Alzheimer's changes
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
Chengdu, SichuanAges 18 years+ - NCT06837272Recruiting
Gut health and brain health in Alzheimer's disease
This study looks at how the bacteria in your gut might be connected to memory and thinking problems in Alzheimer's disease. It may help us understand if changes in the gut can affect brain health.
Jining, ShandongAges 60–80 - NCT06841848Recruiting
Eye camera test for early Alzheimer's
This study is testing a new eye camera to see if it can help find early signs of Alzheimer's disease. It is for people aged 55 and older who either have mild to moderate Alzheimer's or do not have Alzheimer's.
Rome, ItalyAges 55 years+ - NCT07367815RecruitingPhase 1/Phase 2
Stem cells from fat tissue for Alzheimer's disease
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
ToulouseAges 50–85 - NCT05413655RecruitingPhase 2
Oral drug for mild Alzheimer’s disease symptoms
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
TaipeiAges 50–80 - NCT06852326Recruiting
Helping caregivers of people with dementia
This study aims to design a support program for informal caregivers of people with Alzheimer's or similar dementias. It works with doctors, nurses, and other experts to understand what help caregivers need.
AmboiseAges 18 years+ - NCT07341009Recruiting
Study of time processing skills in Alzheimer's disease
This study uses a brain game to measure how people with Alzheimer's disease process the passage of time. The goal is to better understand this ability, which could lead to new ways to support patients.
CaenAges Any age - NCT07328451RecruitingPhase 1
Study of DNL628 for people with early Alzheimer's disease
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
's-HertogenboschAges 18–75 - NCT07332260RecruitingPhase 1
Fecal transplant for Alzheimer's disease
This study tests whether a fecal transplant (transferring healthy bacteria from a donor's stool into your colon) can improve memory and thinking in people with mild to moderate Alzheimer's. You would receive the transplant via colonoscopy and have follow-up brain scans.
Tromsø, TromsAges 18 years+ - NCT07324161Recruiting
Magnetic Brain Stimulation for Alzheimer's Disease
This trial tests whether a non-invasive magnetic brain stimulation treatment (TMS) can help people with mild to moderate Alzheimer's disease. You would receive the treatment and be monitored for safety and benefit.
Fuzhou, FujianAges 50–90 - NCT07323927RecruitingEarly Phase 1
Testing galcanezumab for Alzheimer's disease
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
BeijingAges 50–90 - NCT06874231Recruiting
Brain connectivity marker for Alzheimer's disease
This study uses brain scans to find a marker for Alzheimer's disease. It is looking for people with normal memory, mild memory problems, or mild Alzheimer's, and who can undergo a spinal tap and MRI.
Stockholm, SolnaAges 40–85 - NCT07294885Recruiting
Lymphatic surgery for Alzheimer's disease
This study tests a surgical procedure to connect lymph vessels in the neck to veins, which may help clear waste from the brain in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It is for patients who have not improved after at least 3 months of standard care.
ShenyangAges 50–80 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT05077618Recruiting
Teeth bacteria study in seniors with and without Alzheimer’s
This study looks at the bacteria in the mouth (periodontal microbiota) to see whether they differ between seniors with Alzheimer’s disease and seniors without it. You may be asked for a sample from your gums/teeth and background health information.
Nice, CHU de NICEAges 18–90 - NCT07262645RecruitingPhase 3
Light therapy for mild Alzheimer's disease
This study tests if a near-infrared light therapy device can help improve memory and thinking in people with mild to moderate Alzheimer's disease. It involves daily treatment sessions with the device, and a study partner must be available to help with treatment.
Beijing, Beijing MunicipalityAges 50–85 - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85
Hear when a new Alzheimer Disease or Associated Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer disease or associated disorder?
- Yes. Clin2 currently lists 1,805 recruiting alzheimer disease or associated disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer disease or associated disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer disease or associated disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.